Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to assess the efficacy and safety of repeated administration of G-CSF for the treatment of hot flashes and vasomotor symptoms in women with naturally-occurring or surgically induced menopause. G-CSF will be administered three times at 28 day intervals to postmenopausal women, ages 40 to 65, suffering at least 49 moderate to severe hot flashes per week.


Clinical Trial Description

This is a 12-week, multicenter, randomized, double-blind, placebo-controlled study. Eligible subjects will be stratified by natural or surgical menopause and randomized (1:1) to receive 3 single injections, 28-days apart, of either G-CSF or placebo. This study will consist of a 14-21 day screening period. Subjects enrolled will be given three single 1.0 mL subcutaneous (SC) injections (repeated 28-days apart), in the outer area of either upper arm, of either G-CSF or placebo (sterile physiological saline) at Baseline, Day 28 and Day 56. Subjects will be followed for 12 weeks and will complete hot flash diary entries every day for the duration of treatment. Safety will be assessed by adverse events, clinical laboratory tests (clinical chemistry and complete blood count with differential) and vital signs. A follow-up phone call will occur 60 days after the last dose of study drug. Eligibility will be assessed via physical examination, clinical laboratory testing, vital signs. Subjects will receive a diary in which to record daily hot flashes symptoms during the duration of the screening period. Subjects must have at least 14 days of hot flash recordings to participate in the study. The diary will be reviewed by study site staff on Baseline (Day 0) to confirm study eligibility. During the treatment period, subjects will return to the study site at Days 1, 21, 28, 29, 49, 56, 57, and 84 for assessments. The follow-up phone call will occur approximately 60 days following the last dose of study drug. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03640754
Study type Interventional
Source MenoGeniX, Inc.
Contact
Status Completed
Phase Phase 1
Start date August 6, 2018
Completion date February 22, 2022

See also
  Status Clinical Trial Phase
Not yet recruiting NCT06369363 - Estrogen Deficiency on Cardiovascular Risk Early Phase 1
Not yet recruiting NCT01170195 - Effectiveness of Licorice Extract Dietary Supplement on the Treatment of Postmenopausal Symptoms Phase 1/Phase 2
Completed NCT00535288 - Dose-Finding Safety and Efficacy Trial of Org 50081 (Esmirtazapine) in the Treatment of Vasomotor Symptoms (177001/P06472/MK-8265-013) Phase 3
Recruiting NCT06030388 - Strength and Aerobic Training Against Hot Flushes in Postmenopausal Women N/A
Not yet recruiting NCT05557799 - Photobiomodulation in Post Menopause Genitourinary Syndrome Phase 1/Phase 2
Recruiting NCT04893226 - Time-Restricted Feeding Intervention in Metabolically-Unhealthy Postmenopausal Women N/A
Completed NCT03684096 - Effect of Non-estrogenic Pollen Extract PCC-100 on Hot Flushes N/A
Completed NCT01268046 - Aging and Estrogen on Cortical Function Phase 1/Phase 2
Recruiting NCT05659693 - The Effect of Digital Literacy Education Given to Postmenopausal Women on Health Literacy and Quality of Life N/A
Completed NCT03572153 - A Mind-Body Intervention for Hot Flash Management N/A
Not yet recruiting NCT06419972 - Multimodal Program for Climacteric Women N/A
Not yet recruiting NCT06197568 - Open-Label Study of Vaginal AZU-101 in Postmenopausal Women Phase 1/Phase 2
Withdrawn NCT03854396 - Clinical Trial on the Preventive Effect of Intravaginal Prasterone on Recurrent Urinary Tract Infections in Postmenopausal Women Phase 3
Completed NCT01361308 - Efficacy/Safety Study of Brisdelleā„¢ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS) Phase 3
Unknown status NCT00905723 - The Effects of Isoflavone and Estrogen in Sex Response in Climacteric Women Phase 3
Recruiting NCT05351476 - Exercise Training and Fat Metabolism in Postmenopausal Women N/A
Completed NCT06096818 - Kegel and Abdominal Exercises on Urinary Incontinence Severity, Quality of Life, and Sleep Quality in Menopausal Women N/A
Completed NCT03150407 - Use of J3 Bioscience Lubricating Intravaginal Ring VR101 to Relieve the Symptoms of Vaginal Dryness N/A
Recruiting NCT06220266 - Effects of Phytoestrogen From Pueraria Mirifica in Improvement of Serum Lipid Parameters in Postmenopausal Women Phase 2/Phase 3
Recruiting NCT04129060 - Cholinergic Health After Menopause (CHAMP) Early Phase 1